Is Knowledge of Hemodynamics Really Dangerous?

Jakobsen, Carl-Johan

doi:10.1053/j.jvca.2016.02.017

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The abnormal expression of TLR3 has been reported on various of cancer tissues (10,11). TLR3 has also been recognized as a favorable prognosis biomarker of lung cancer by activating apoptosis or promoting autophagy (12,13). TLR3 agonist enhanced T cell infiltration in lung tissue, which is essential for tumor immunity within the tumor microenvironment (14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma

Tian

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

This study aims to analyze the methylation regulation of TLR3 in lung adenocarcinoma (LUAD) and to explore the association of TLR3 expression with immune microenvironment. TLR3 has a decreased expression in LUAD tissues and low expression of TLR3 is not only associated with poor prognosis in patients with LUAD, but also can be used as a diagnostic marker. Bisulfite sequencing PCR (BSP) results showed that the methylation level in the promoter of TLR3 was negatively correlated with the level of TLR3 mRNA in LUAD tissues. TIMER analysis showed that TLR3 was negatively correlated with the tumor purity of LUAD and positively with immune cell infiltration to some extent. ESTIMATE analysis also suggested that TLR3 expression and its methylation had significant correlation with immune score. The lower immune scores were associated with the late stage of LUAD and poor prognosis. The high expression of TLR3 might inhibit the development of LUAD by activating apoptosis pathway. The proteins interacted with TLR3 were mainly involved in the apoptosis pathway and positively correlated with the key genes (MYD88, Caspase 8, BIRC3, PIK3R1) in this pathway. Therefore, TLR3 as a key biomarker for prognosis and diagnosis in LUAD, might be considered as a potential epigenetic and immunotherapeutic target.

show abstract

Section: Introductionmentioning

confidence: 99%

Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma

Tian

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…High TLR3 expression has been associated with a good prognosis in NSCLC, HCC and neuroblastoma [26,[30][31][32]. TLR3 activation in vitro has been shown to induce apoptosis in the lung cancer cell lines Calu-3 (adenocarcinoma) and H460 (large cell carcinoma), and is associated with caspase-3 activation in human adenocarcinoma NSCLC tissue [33]. Moreover, TLR3 expression in cancer cells activated the CD103+ lung dendritic cell subset, which is specifically associated with the processing of antigens derived from apoptotic cells and their presentation to CD8 T cells [34].…”

Section: Tlr3-mostly Anti-tumoral Effects Mediated By Dendritic Cells...mentioning

confidence: 99%

Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities

2023

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are indispensable for the activation, maintenance and halting of immune responses. TLRs can mediate inflammation by recognizing molecular patterns in microbes (pathogen-associated molecular patterns: PAMPs) and endogenous ligands (danger-associated molecular patterns: DAMPs) released by injured or dead cells. For this reason, TLR ligands have attracted much attention in recent years in many cancer vaccines, alone or in combination with immunotherapy, chemotherapy and radiotherapy (RT). TLRs have been shown to play controversial roles in cancer, depending on various factors that can mediate tumor progression or apoptosis. Several TLR agonists have reached clinical trials and are being evaluated in combination with standard of care therapies, including RT. Despite their prolific and central role in mediating immune responses, the role of TLRs in cancer, particularly in response to radiation, remains poorly understood. Radiation is recognized as either a direct stimulant of TLR pathways, or indirectly through the damage it causes to target cells that subsequently activate TLRs. These effects can mediate pro-tumoral and anti-tumoral effects depending on various factors such as radiation dose and fractionation, as well as host genomic features. In this review, we examine how TLR signaling affects tumor response to RT, and we provide a framework for the design of TLR-based therapies with RT.

show abstract

Is Knowledge of Hemodynamics Really Dangerous?

Cited by 2 publications

References 37 publications

Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma

Methylation Regulation of TLR3 on Immune Parameters in Lung Adenocarcinoma

Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities

Contact Info

Product

Resources

About